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Background: Health-related quality of life (QOL) is an
important issue in post-transplant care of long-term survi-
vors after hematopoietic stem cell transplantation (HSCT).
We conducted a single-center cross-sectional analysis of
medical and socio-demographic factors affecting on the QOL
outcomes in HSCT recipients.
Patients and Methods: This analysis included 152 Japanese
adult patients surviving more than 2 years after allogeneic
HSCT in Toranomon Hospital, who were enrolled at a median
of 5.4 (2.0-18.4) years from HSCT. Patient-reported QOL was
assessed using two questionnaires (FACT-BMT and SF-36),
and physical exams and laboratory tests for screening post-
transplant complications were principally performed at the
time of QOL survey completion. Chronic graft-versus-host
disease (cGVHD) severity was determined by NIH consensus
criteria. Socio-demographic data was collected through self-
report and chart review.
Results: The median age at enrollment was 55 (23-75) years
old. Thirty-eight patients received related donor grafts, while
58 and 56 received unrelated cord blood and bone marrow.
One hundred received reduced-intensity conditioning.
cGVHD were observed in 127 patients (severe in 17,
moderate in 65, mild in 45), the most commonly involved
organ of which was eyes (51.3%), followed by skin (50%) and
mouth (34.9%). Forty-six patients had other late complica-
tions (endocrine disorders in 9, bone events in 22, ocular
events in 22, and secondary malignancies in 5). The differ-
ences according to interval from HSCT were not seen in all
composite score and subscales of the two questionnaires
except physical well-being score (PWB) of the FACT-BMT
during the late post-transplant period. Although the FACT-
BMT total score was not signiﬁcantly different between
patients who had any cGVHD and those who did not, it
progressively decreased with increasing cGVHD severity and
signiﬁcantly lower for severe cGVHD compared to moderate
cGVHD (P¼ 0.01, Figure 1A). Severe cGVHD had a remarkable
adverse impact on physical aspects of QOL (the physical
component score (PCS) of the SF-36 and PWB, both P < .001,
Figure 1B). Oral, gastrointestinal, musculoskeletal and
pulmonary involvement was strongly associated with poor
QOL. Multivariable logistic regression analysis revealed the
positive impact of employment status on physical and
functional aspects of QOL (PCS: HR 0.41, P ¼ .018 and the
functional well-being score (FWB) of the FACT-BMT: HR 0.27,
P < .001), in addition to the signiﬁcant correlation between
cGVHD severity and the perception of QOL. The FWB was
signiﬁcantly higher in patients with severe cGVHD who had
a work compared to those who did not (P ¼ 0.02).Discussion: The impairment of QOL was particularly prom-
inent among the patients with severe cGVHD. Preventing
severe cGVHD and promoting reintegration into society
might improve overall QOL outcome in long-term survivors
after HSCT.
Figure 1. Quality of life scores according to cGVHD severity.74
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Objective: Increase in the number of hematopoietic stem cell
transplantation (HCT) and its improvement has led to
increase in the number of long-term survivors post HCT. We
have assessed risks of late mortality and causes of death
among long term survivors after allogeneic hematopoietic
stem cell transplantation (HCT).
Patients and Methods: 10,512 recipients of ﬁrst allogeneic
HCT for hematological diseases, who were relapse-free
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for analyses. Median age at transplant was 29 (range, 0-76).
58% received stem cells from related donors. 78% received
bone marrow, 14% received peripheral blood stem cell, and
8% received cord blood. 77% received myeloablative condi-
tioning. Median follow-up for survivors was 7 years (range, 2
to 28). A total of 57,766 person-years were observed. 6,884
recipients were followed for more than 5 years (32,438
person years for observation period of 5 years or longer).
Standarized mortality ratio (observed / expected ratio) was
calculated for comparison with general population in Japan
for speciﬁc causes of death.
Results: Among relapse-free survivors at 2 years, overall
survival at 10 years, 15years were 86%, and 82%. Probabilities
were 95% and 91% when subjects were limited to relapse-
free survivors at 5 years. When compared to general pop-
ulation in Japan, risk of overall mortality was signiﬁcantly
higher (observed / expected ratio [O/E] ¼ 15.1, 95%CI, 14.3-
16.0). The risk of mortality was signiﬁcantly higher with
infection (O/E¼89.8, 95%CI, 77.4-100.7), new malignancy (O/
E¼3.2, 95%CI, 2.6-4.0), cardiovascular (O/E¼2.3, 95%CI, 1.5-
3.5), respiratory (O/E¼150.9, 95%CI, 131.1-172.5) including
chronic obstructive lung disease (O/E¼182.2, 95%CI, 101.2-
214.1), digestive (O/E¼4.2, 95%CI, 1.4-9.7), liver (O/E¼10.5,
95%CI, 7.4-14.8), kidney-genitourinary (O/E¼23.6, 95%CI,
13.1-37.1), and external cause (O/E¼2.5, 95%CI, 1.5-3.8)
compared to general population. The risk of death from any
cause was approximately twenty times higher from 2 to 4
years after transplant for relapse-free survivors at 2 years (O/
E¼21.1, 95%CI, 19.6-22.6) compared to general population.
The risk was still ten times higher with statistical signiﬁcance
for the subjects after 5 years post transplant (O/E¼10.0, 95%
CI, 9.1-11.0).
Conclusions: Long-term survivors after allogeneic HCTare at
higher risk of mortality due to various causes other than
underlying diseases. Screening and preventive practices are
important for long-term follow up of HCT recipients.75
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Late onset non-infectious pulmonary injury complicates
>10% of allogeneic stem cell transplants (SCT), particularly in
subjects conditioned with high dose Total Body Irradiation
(TBI), and contributes to transplant related mortality. To
characterize the kinetics of recovery from pulmonary injury
in long term survivors we collected data on 138 (78 male, 60
female) subjects surviving>5 years after SCT from their HLA-
matched siblings. The median age at transplant was 36 years.
Transplant indications were CML (63), AML (31), MDS (19),
ALL (12) and others (14). 126 subjects received 1200 cGy
TBI-based conditioning with or without lung shielding, 3
received 400 cGy TBI-based conditioning and 9 patients
received no irradiation. Ex vivo T cell depleted grafts were
given to 131 recipients, except for six who received a non-
myeloablative SCT. Of the 138 long term survivors, 26 had no
cGvHD, 70 had cGvHD lasting less than 3 years; and 42 had
prolonged cGvHD requiring systemic immunosuppression
for> 3 years. Among the 17 patients who died after 5 years, 4died of pulmonary causes, including two with lung cancer.
Pre-transplant abnormalities (< 80% predicted) in PFTs were
found in 15.9% of subjects in the following declining
frequency: FVC%, VC, TLC, FEV1, DLCO_Adj (adjusted for
hemoglobin and alveolar ventilation) Hb/VA and FEV1/FVC.
Baseline (BL) PFTs served as the reference for all subsequent
measurements at 3, 5, 10 and 15 years for each survivor. The
only parameter showing a clinically signiﬁcant decline post
transplant was DLCO_Adj which reached a nadir at 5 years,
with subsequent normalization at the 10 yearmark [paired t-
test]. An abnormal (<80% of baseline) DLCOAdj was found in
19.6, 21.0, 0.7 and 0% of survivors at 3, 5, 10 and 15 years. The
mean DLCO_Adj at 3, 5, 10 and 15 years were 91% (P ¼ .003),
88% (P < .001), 98% (p¼NS) and 100% (p¼NS) of BL, respec-
tively. Multivariable modeling (forward-stepwise multiple
regression) identiﬁed the presence of chronic GVHD
(P ¼ .017) and abnormal Baseline DLCO_Adj (P ¼ .023) as the
only signiﬁcant factors associated with the decline in
DLCO_Adj at 5 years but excluded smoking, conditioning
intensity, baseline C-reactive protein level, TBI dose to the
lungs and demographic variables. In conclusion, DLCO_Adj is
the only PFT marker associated with pulmonary injury in our
TBI-conditioned transplant population. DLCO_Adj nadirs at 5
years post-SCT, and normalizes by 10 years. Chronic GVHD
and pre-transplant DLCO_Adj are important contributory
factors to the decline in DLCO_Adj.76
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Background: Several recent studies have examined the use
of sirolimus (SIR) and tacrolimus (TAC) for prevention of
graft-versus-host disease (GVHD). Data are sparse, however,
regarding patient-reported quality of life (QOL) associated
with this regimen. We report an analysis of QOL outcomes in
the ﬁrst year post-transplant from a randomized controlled
trial of (SIR/TAC) compared to methotrexate (MTX)/TAC.
